S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   443.89 (-0.21%)
AAPL   171.13 (-1.26%)
MSFT   420.22 (-0.29%)
META   488.40 (-1.11%)
GOOGL   150.71 (-0.11%)
AMZN   180.36 (+0.29%)
TSLA   177.22 (-1.45%)
NVDA   906.97 (+0.50%)
NIO   4.54 (-2.78%)
AMD   180.82 (+0.68%)
BABA   72.46 (+1.22%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.91 (-1.03%)
CGC   9.07 (-5.03%)
GE   174.74 (-2.99%)
DIS   122.72 (+1.44%)
AMC   3.69 (-14.98%)
PFE   28.08 (+1.08%)
PYPL   67.24 (+1.01%)
XOM   115.87 (+0.78%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   443.89 (-0.21%)
AAPL   171.13 (-1.26%)
MSFT   420.22 (-0.29%)
META   488.40 (-1.11%)
GOOGL   150.71 (-0.11%)
AMZN   180.36 (+0.29%)
TSLA   177.22 (-1.45%)
NVDA   906.97 (+0.50%)
NIO   4.54 (-2.78%)
AMD   180.82 (+0.68%)
BABA   72.46 (+1.22%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.91 (-1.03%)
CGC   9.07 (-5.03%)
GE   174.74 (-2.99%)
DIS   122.72 (+1.44%)
AMC   3.69 (-14.98%)
PFE   28.08 (+1.08%)
PYPL   67.24 (+1.01%)
XOM   115.87 (+0.78%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   443.89 (-0.21%)
AAPL   171.13 (-1.26%)
MSFT   420.22 (-0.29%)
META   488.40 (-1.11%)
GOOGL   150.71 (-0.11%)
AMZN   180.36 (+0.29%)
TSLA   177.22 (-1.45%)
NVDA   906.97 (+0.50%)
NIO   4.54 (-2.78%)
AMD   180.82 (+0.68%)
BABA   72.46 (+1.22%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.91 (-1.03%)
CGC   9.07 (-5.03%)
GE   174.74 (-2.99%)
DIS   122.72 (+1.44%)
AMC   3.69 (-14.98%)
PFE   28.08 (+1.08%)
PYPL   67.24 (+1.01%)
XOM   115.87 (+0.78%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   443.89 (-0.21%)
AAPL   171.13 (-1.26%)
MSFT   420.22 (-0.29%)
META   488.40 (-1.11%)
GOOGL   150.71 (-0.11%)
AMZN   180.36 (+0.29%)
TSLA   177.22 (-1.45%)
NVDA   906.97 (+0.50%)
NIO   4.54 (-2.78%)
AMD   180.82 (+0.68%)
BABA   72.46 (+1.22%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.91 (-1.03%)
CGC   9.07 (-5.03%)
GE   174.74 (-2.99%)
DIS   122.72 (+1.44%)
AMC   3.69 (-14.98%)
PFE   28.08 (+1.08%)
PYPL   67.24 (+1.01%)
XOM   115.87 (+0.78%)
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$40.39
$40.39
50-Day Range
$38.66
$40.39
52-Week Range
$18.34
$40.51
Volume
N/A
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.25
KDNY stock logo

About Chinook Therapeutics Stock (NASDAQ:KDNY)

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

KDNY Stock News Headlines

Chinook Elementary
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Chinook Therapeutics, Inc. (KDNY)
Expert Ratings for Chinook Therapeutics
Chinook Therapeutics (NASDAQ: KDNY)
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Why Are Chinook Therapeutics Shares Trading Higher Today
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Novartis Buys Chinook: M&A To Drive Future Growth
Chinook Shareholder Action Reminder
Chinook Shareholder Notice
Chinook Investor Alert
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.25
High Stock Price Target
$42.00
Low Stock Price Target
$32.00
Potential Upside/Downside
-7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%

Debt

Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share

Miscellaneous

Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


KDNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings
or view top-rated stocks.

What is Chinook Therapeutics' stock price target for 2024?

11 brokerages have issued 1 year price targets for Chinook Therapeutics' stock. Their KDNY share price targets range from $32.00 to $42.00. On average, they anticipate the company's stock price to reach $37.25 in the next year. This suggests that the stock has a possible downside of 7.8%.
View analysts price targets for KDNY
or view top-rated stocks among Wall Street analysts.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.03. The business had revenue of $1.83 million for the quarter, compared to the consensus estimate of $0.14 million. Chinook Therapeutics had a negative net margin of 4,199.93% and a negative trailing twelve-month return on equity of 58.28%. Chinook Therapeutics's quarterly revenue was down 32.2% on a year-over-year basis.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

This page (NASDAQ:KDNY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners